作为药物研发黑洞,代谢功能障碍相关脂肪性肝炎(MASH,曾称为NASH)领域的失利还在增加。近日,吉利德宣布已终止与韩国生物技术公司Yuhan就两种MASH疗法的合作和许可协议,此举经双方共同同意。据了解,MASH的发生与脂肪酸积累、胰岛素抵抗、免疫信号异常、炎症细胞等都有关系,但最关键的致病途径仍不明确。自20世纪80年代MASH被首次命名并提出以来,相关领域临床新药研发就成为一座全球制药企业都...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.